|

NKX019 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since May 2026

Also known as: NKX019 infusion

Pipeline

Phase 1/2: 2

Top Sponsors

  • Nkarta, Inc.2

Indications

  • Antineutrophil Cytoplasmic Antibody-Associated Vasculitis1
  • Systemic Sclerosis1
  • Lupus Nephritis1
  • Primary Membranous Nephropathy1
  • Idiopathic Inflammatory Myopathies1

Little Rock, Arkansas1 trial

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Nkarta Investigational Site

Phase 1/2

Orange, California1 trial

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Nkarta Investigational Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.